Lakefront Biotherapeutics Initiates €50 Million Share Repurchase Program

On June 9, 2026, Lakefront Biotherapeutics (formerly known as Galapagos) announced the initiation of a share repurchase program. Under this program, the company is authorized to repurchase its ordinary shares for an aggregate amount of up to €50 million. The program is scheduled to conclude no later than December 31, 2026, and is being executed in partnership with Morgan Stanley & Co International PLC. This buyback initiative follows a March 2026 transaction with Gilead, which provided Lakefront the opportunity to repurchase up to $150 million of shares, subject to available distributable reserves. The company stated that the objective of the program is to deliver shareholder value, and the repurchased shares will be held as treasury shares. The program was approved during the Extraordinary Shareholders’ Meeting held on April 28, 2026. Lakefront retains the right to suspend or terminate the repurchase program at any time. The company continues to focus its strategic efforts on oncology, immunology, and inflammation programs.